Despite a dip in M&A value and volume, PwC predicts deal activity to remain strong with an uptick in IPOs
The last 12 months have seen some of the biggest M&A deals in recent years — think Pfizer’s $43 billion acquisition of Seagen and Merck’s nearly $11 billion buyout of Prometheus Biosciences — but overall deal value and volume have dipped, according to a mid-year PwC report.
Since May 15 of last year, deal value declined by 3% to $213.4 billion and deal volume was down 29% to 231.
But researchers at PwC aren’t all doom and gloom, and they have a few recommendations: Despite challenging debt markets, high inflation, lower IPO volumes and an uncertain economy, they expect overall deal activity to “remain strong” in the second half of 2023 with the potential for an IPO rebound.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
